We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-10.25%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.19B
AUM Growth
-$1.8B
Cap. Flow
-$1.09B
Cap. Flow %
-34.19%
Top 10 Hldgs %
52.73%
Holding
142
New
9
Increased
15
Reduced
47
Closed
31

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$32.3M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$32.3M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.9M
4
LLY icon
Eli Lilly
LLY
+$30M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$24.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$143M
2
APLS
Apellis Pharmaceuticals
APLS
+$52.9M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$39.4M
4
NVRO
NEVRO CORP.
NVRO
+$34.5M
5
TVTX icon
Travere Therapeutics
TVTX
+$32.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.5%
2 Financials 0.29%
3 Consumer Discretionary 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
101
Protara Therapeutics
TARA
$214M
$850K 0.03%
290,051
-93,475
-24% -$342K
AGRX
102
DELISTED
Agile Therapeutics
AGRX
$620K 0.02%
10,647
– –
MOTS
103
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$507K 0.02%
6,002
– –
PRVB
104
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$443K 0.01%
110,728
-680,821
-86% -$3.23M
EQRXW
105
DELISTED
EQRx, Inc. Warrant
EQRXW
$203K 0.01%
250,000
– –
NEPT
106
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$81K ﹤0.01%
1,429
– –
CMAXW
107
DELISTED
CareMax, Inc. Warrant
CMAXW
$43K ﹤0.01%
60,000
– –
SRZNW icon
108
Surrozen Inc Warrant
SRZNW
$36.6K
$32K ﹤0.01%
166,666
– –
SRZN icon
109
Surrozen
SRZN
$223M
$18K ﹤0.01%
401
-4,781
-92% -$195K
ACAD icon
110
Acadia Pharmaceuticals
ACAD
$4.5B
– –
-284,853
Closed -$6.9M
BFLY.WS
111
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
– –
-233,333
Closed -$238K
EVH icon
112
Evolent Health
EVH
$370M
– –
-250,000
Closed -$8.07M
IMRX icon
113
Immuneering
IMRX
$262M
– –
-681,051
Closed -$4.41M
LEGN icon
114
Legend Biotech
LEGN
$3.65B
– –
-616,141
Closed -$22.4M
LUNG icon
115
Pulmonx
LUNG
$52.8M
– –
-537,779
Closed -$13.3M
MRUS
116
DELISTED
Merus
MRUS
– –
-209,046
Closed -$5.53M
OBIO icon
117
Orchestra BioMed
OBIO
$228M
– –
-450,000
Closed -$4.46M
PEN icon
118
Penumbra
PEN
$12.6B
– –
-143,591
Closed -$31.9M
PRTA icon
119
Prothena Corp
PRTA
$448M
– –
-65,144
Closed -$2.38M
RCUS icon
120
Arcus Biosciences
RCUS
$3.32B
– –
-405,000
Closed -$12.8M
RPID icon
121
Rapid Micro Biosystems
RPID
$102M
– –
-190,745
Closed -$1.29M
SGHT icon
122
Sight Sciences
SGHT
$289M
– –
-390,000
Closed -$4.51M
ZNTL icon
123
Zentalis Pharmaceuticals
ZNTL
$330M
– –
-501,509
Closed -$23.1M
LENZ
124
LENZ Therapeutics
LENZ
$178M
– –
-46,551
Closed -$1.66M
ACCD
125
DELISTED
Accolade Inc
ACCD
– –
-330,682
Closed -$5.81M
2 3 4
5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Perceptive Advisors held 142 positions worth $3.19B, down 36% from $4.99B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors withdrew a net $1.09B in Q2 2022, closing 31 positions and reducing 47 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $143M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Seagen Inc. Common Stock worth $39.6M.

  • Perceptive Advisors's largest Q2 2022 buy was Seagen Inc. Common Stock: 224,000 shares worth $39.6M.
  • Perceptive Advisors added most to LYRA THERAPEUTICS INC in Q2 2022, an estimated $32.3M increase.
  • Perceptive Advisors's biggest Q2 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $52.9M.
  • Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, selling an estimated $143M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.19B portfolio in Q2 2022.
  • Perceptive Advisors opened 9 new positions and closed 31 in Q2 2022.
  • Perceptive Advisors's portfolio value fell 36% quarter-over-quarter to $3.19B.

Based on Perceptive Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.